<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">

PROTEOMICS

Enzyme-linked immunosorbent assay

A targeted and quantitative method for interpreting a patient's immune response to cancer by measuring blood levels of autoantibodies to tumor-associated antigens.

ELISA Platform Overview

We use enzyme-linked immunosorbent assays (ELISA) to quantitatively test for the presence of autoantibodies in patient blood samples using tumor-associated antigens that are highly specific for the autoantibodies of interest. ELISA is an established diagnostic testing technique that is known for its sensitivity, reproducibility, rapid procedure, and high throughput.

Key Benefits of ELISA​

bdx-tube-icon Flexible Sample Types Blood, Saliva, Urine
icon-chart Absolute Quantification
bdx-clock-icon Rapid Testing Turnaround​
icon-multitarget Targeted Proteomics
bdx-target-icon High Throughput & Reproducibility​
bdx-doctor-icon Established Clinical Dx Testing

Our ELISA Testing Solutions​

Nodify CDT™ Lung Nodule Test

  • Nodify CDT​ stratifies patients with incidental lung nodules by risk of malignancy
  • Integrates clinical risk assessment with proteomic insights from a simple blood draw
  • Results support clinical decision-making to help physicians more efficiently manage incidental nodules
Learn more about the Nodify CDT test

Custom ELISA Assay

  • We develop custom blood-based ELISA assays based on your individual needs.
  • We can analytically and clinically validate ELISA assays in our CLIA/CAP/NYS CLEP/ISO 13485-certified laboratory.
  • Our partners use our in-house ELISA technology for preclinical biomarker work, retrospective analyses, clinical study enrollment, treatment monitoring, and coordinated commercial deployment. 

Get in touch

Contact Us

What we do

learn more

Data library

Discover More

Interested in another topic?